BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35615262)

  • 1. Redirecting anti-Vaccinia virus T cell immunity for cancer treatment by AAV-mediated delivery of the VV B8R gene.
    Cao D; Song Q; Li J; Chard Dunmall LS; Jiang Y; Qin B; Wang J; Guo H; Cheng Z; Wang Z; Lemoine NR; Lu S; Wang Y
    Mol Ther Oncolytics; 2022 Jun; 25():264-275. PubMed ID: 35615262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).
    Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J
    EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade.
    Zuo S; Wei M; Xu T; Kong L; He B; Wang S; Wang S; Wu J; Dong J; Wei J
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34949694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A soluble chemokine-binding protein from vaccinia virus reduces virus virulence and the inflammatory response to infection.
    Reading PC; Symons JA; Smith GL
    J Immunol; 2003 Feb; 170(3):1435-42. PubMed ID: 12538705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccinia virus vectors with an inactivated gamma interferon receptor homolog gene (B8R) are attenuated In vivo without a concomitant reduction in immunogenicity.
    Verardi PH; Jones LA; Aziz FH; Ahmad S; Yilma TD
    J Virol; 2001 Jan; 75(1):11-8. PubMed ID: 11119568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immediate-early expression of a recombinant antigen by modified vaccinia virus ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responses.
    Baur K; Brinkmann K; Schweneker M; Pätzold J; Meisinger-Henschel C; Hermann J; Steigerwald R; Chaplin P; Suter M; Hausmann J
    J Virol; 2010 Sep; 84(17):8743-52. PubMed ID: 20538860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines.
    Moon EK; Wang LS; Bekdache K; Lynn RC; Lo A; Thorne SH; Albelda SM
    Oncoimmunology; 2018; 7(3):e1395997. PubMed ID: 29399394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic vaccinia virus expressing a bispecific T-cell engager enhances immune responses in EpCAM positive solid tumors.
    Wei M; Zuo S; Chen Z; Qian P; Zhang Y; Kong L; Gao H; Wei J; Dong J
    Front Immunol; 2022; 13():1017574. PubMed ID: 36451817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses.
    Feder-Mengus C; Schultz-Thater E; Oertli D; Marti WR; Heberer M; Spagnoli GC; Zajac P
    Hum Gene Ther; 2005 Mar; 16(3):348-60. PubMed ID: 15812230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A study of the vaccinia virus interferon-gamma receptor and its contribution to virus virulence.
    Symons JA; Tscharke DC; Price N; Smith GL
    J Gen Virol; 2002 Aug; 83(Pt 8):1953-1964. PubMed ID: 12124459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The construction of attenuated Tiantan recombinant vaccinia virus vector with IFN-gamma receptor gene deletion].
    Huang W; Liu Y; Duan DL; Li HS; Liu Y; Hong KX; Zhu JH; Shao YM
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2004 Mar; 18(1):43-6. PubMed ID: 15340525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope.
    Harrington LE; Most Rv Rv; Whitton JL; Ahmed R
    J Virol; 2002 Apr; 76(7):3329-37. PubMed ID: 11884558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment of tumor-specific immunotherapy model utilizing vaccinia virus-reactive helper T cell activity.
    Shimizu Y; Hasumi K; Masubuchi K; Okudaira Y
    Eur J Immunol; 1988 Nov; 18(11):1773-8. PubMed ID: 2974424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccinia virus homologues of the Shope fibroma virus inverted terminal repeat proteins and a discontinuous ORF related to the tumor necrosis factor receptor family.
    Howard ST; Chan YS; Smith GL
    Virology; 1991 Feb; 180(2):633-47. PubMed ID: 1846491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccinia virus infection of mature dendritic cells results in activation of virus-specific naïve CD8+ T cells: a potential mechanism for direct presentation.
    Yates NL; Alexander-Miller MA
    Virology; 2007 Mar; 359(2):349-61. PubMed ID: 17056088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection against vaccinia virus challenge by CD8 memory T cells resolved by molecular mimicry.
    Cornberg M; Sheridan BS; Saccoccio FM; Brehm MA; Selin LK
    J Virol; 2007 Jan; 81(2):934-44. PubMed ID: 17079318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attenuation of a vaccine strain of vaccinia virus via inactivation of interferon viroceptor.
    Dénes B; Gridley DS; Fodor N; Takátsy Z; Timiryasova TM; Fodor I
    J Gene Med; 2006 Jul; 8(7):814-23. PubMed ID: 16634110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systemically deliverable Vaccinia virus with increased capacity for intertumoral and intratumoral spread effectively treats pancreatic cancer.
    Marelli G; Chard Dunmall LS; Yuan M; Di Gioia C; Miao J; Cheng Z; Zhang Z; Liu P; Ahmed J; Gangeswaran R; Lemoine N; Wang Y
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33500259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virus-encoded ectopic CD74 enhances poxvirus vaccine efficacy.
    Walline CC; Deffit SN; Wang N; Guindon LM; Crotzer VL; Liu J; Hollister K; Eisenlohr LC; Brutkiewicz RR; Kaplan MH; Blum JS
    Immunology; 2014 Apr; 141(4):531-9. PubMed ID: 24205828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Qualitative differences in cellular immunogenicity elicited by hepatitis C virus T-Cell vaccines employing prime-boost regimens.
    Tan WG; Zubkova I; Kachko A; Wells F; Adler H; Sutter G; Major ME
    PLoS One; 2017; 12(7):e0181578. PubMed ID: 28732046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.